Supriya Lifescience Ltd

- The company is currently debt-free with strong cash positions. - They do not utilize any working capital limits except for letters of credit and bank guarantees. - No borrowings have been utilized in the last six months. - There is no mention of any planned fundraising through debt or equity in the current or near future. - The company appears focused on organic growth funded through internal accruals and careful capex planning (INR 100 crores planned for FY25).

- Capex of about INR 100 crores anticipated in FY25, mainly for the Ambernath facility and new Module E. - Module E is expected to be commissioned by end of the current month, with commercial production starting by Q2 FY25. - Ambernath facility is also scheduled to be ready by Q2 FY25 to expand CMO and CDMO activities. - An additional capex of approximately INR 75 crores for Ambernath has already been spent. - Debottlenecking activities are ongoing to enhance capacity at the current product basket. - The new capacities at Lote will reach around 1020 KL, and Ambernath will add approximately 200 KL. - Capex and capacity expansion aim to support the scaling up of CMO/CDMO projects, expecting 18-20% of revenue from these by FY27.

- The company targets 20%+ annual revenue growth driven by a blended portfolio including existing products, new product launches, and CMO/CDMO activities. - Peak revenue from the DSM contract is expected around INR60-70 crores with anticipated 20-25 metric tons supply in FY '25. - New product launches in regulated markets, including anaesthetic, anti-diabetic, and anti-anxiety categories, are expected to significantly contribute starting FY '25. - CMO/CDMO segment is forecasted to contribute 18-20% of total revenue by FY '27, with Amarnath facility advancing capacity. - The oral cancer detection kit is scheduled for launch in ~2 years following clinical trials. - Capacity utilization currently at ~86%, with new modules (Amarnath and Module E) commissioning by Q2 FY '25; full-scale production to take 2-3 years. - Regulated market share is increasing, stabilizing revenue with diversified product basket mitigating seasonality effects.

- The company targets 20%+ revenue growth year-on-year, aiming for around INR 1,000 crores revenue by FY27. - EBITDA margin guidance is maintained at a steady 28%-30%, with potential for improvement through new premium-margin projects. - CMO/CDMO business is expected to contribute 18%-20% of total revenue by FY27, offering better margin profiles. - New product launches in regulated markets and expanded CMO/CDMO capabilities (including Ambernath and module E facilities) are key growth drivers. - Clinical trials for the oral cancer detection kit are underway; product launch anticipated in about 2 years, adding future revenue streams. - Operational efficiencies have improved working capital cycles and reduced borrowing needs, positively impacting profitability. - Stable and improving margins expected due to better product mix and regulated market focus. - Overall profits and EPS are expected to grow in line with revenue and margin expansions driven by strategic investments and product pipeline.

- The company has several advanced-stage CMO projects with volume commitments and signed binding contracts expected to scale up over the next 2-3 years. - The DSM contract is a significant existing order, with expected material supply of 20-25 metric tons in FY '25, generating peak revenues of INR 60-70 crores. - The Ambernath facility capex is underway and expected to contribute to capacity but peak revenue generation from Ambernath is anticipated later than FY '25. - Registrations in Brazil have opened up a sizable market expected to add around INR 200 crores to the topline over the next 3 years. - The company is scaling up new products and expecting commercial production startups imminently for validation batch supplied CMO opportunities. - Overall confidence expressed on achieving INR 1000 crores topline with ~18-20% from CMO/CDMO by FY '27, supported by a diversified and de-risked product portfolio.